ER+/HER2-breast cancer
Drug research and approvals for ER+/HER2-breast cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 95 studies of ER+/HER2-breast cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 11 drug trials for it since 2013.
- Recruiting worldwide: 95
- Trials authorized in Canada: 11
- FDA orphan approvals: 0
- EU medicines: 0
Newest posted first, of 95 recruiting on ClinicalTrials.gov ↗
- Short-Term Reduced Dietary Protein in ER+/HER2- Breast Cancer Patients During Neoadjuvant ChemotherapyNCT07897344 · Not applicable · Josephine Connolly-Schoonen · starts Nov 3, 2026
- A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative)…NCT07827573 · Phase 3 · Hoffmann-La Roche · starts Nov 30, 2026
- A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast CancerNCT07766018 · Phase 2 · Stemline Therapeutics, Inc. · starts Aug 18, 2026
- Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving SurgeryNCT07762885 · Phase 3 · Fudan University · starts Jul 1, 2026
- A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerNCT07647328 · Phase 3 · AstraZeneca · starts Jun 15, 2026
- Capecitabine in ER+/HER2-negative Breast CancerNCT07631052 · Phase 2 · University Health Network, Toronto · starts Jul 29, 2026
- Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly…NCT07616453 · Phase 2 · Second Affiliated Hospital, Zhejiang University, School of Medicine · starts May 6, 2026
- Elacestrant in Advanced Triple Positive Breast CancerNCT07612215 · Phase 1 / Phase 2 · NYU Langone Health · starts May 13, 2026
- Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast CancerNCT07563595 · Not reported · iOMEDICO AG · starts Jun 19, 2026
The 10 newest of 11; search them all in Canada trials
| Aug 31, 2026 | A phase IIIb, single-arm, open-label, multicenter study evaluating the treatment adherence, tolerability, and patient-reported outcomes of giredestrant in…Giredestrant (GDC-9545, RO7197597) / Leuprolide / Triptorelin | Roche | Ongoing |
| Aug 29, 2025 | A phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of…Palazestrant (OP-1250) / Letrozole / Ribociclib (LEE011) | Olema Pharmaceuticals | Ongoing |
| Aug 6, 2025 | Capecitabine for targeted eradication of arising ctdna molecular residual disease in er+/HER2- negative breast cancerCapecitabine | University Health Network | Ongoing |
| Feb 14, 2024 | A phase I/II, open-label, multi-center trial of [177lu]lu-neob in combination with capecitabine in adult patients with grpr+, er+, HER2- metastatic breast…[177LU]LU-NEOB (AAA603) / [68GA]GA-NEOB (AAA503) / Capecitabine | Novartis Pharmaceuticals | Ongoing |
| Jul 14, 2023 | A randomized phase II window of opportunity clinical trial of PD-1 +/- IL-4 inhibition early stage er+HER2- breast cancerCemiplimab / Dupilumab | Ottawa Hospital Research Institute | Pending |
| Jun 26, 2023 | A randomized phase 2 non-inferiority trial of (z)-endoxifen and exemestane + goserelin as neoadjuvant treatment for premenopausal women with er+/HER2- breast…Endoxifen/ Exemestane/ Goserelin | Atossa Therapeutics, Inc. | Pending |
| Nov 14, 2022 | A liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant er+/HER2- metastatic breast cancerNiraparib / CFI-400945 / CFI-402257 / Sacituzumab govitecan | Canadian Cancer Trials Group, Cancer Research Institute, Queen's University | Ongoing |
| May 20, 2022 | A phase 1b trial of ARV-471 in combination with everolimus in patients with er+, HER2- advanced or metastatic breast cancerARV-471 / Everolimus | Arvinas Estrogen Receptor Inc. | Pending |
| Nov 9, 2020 | A phase III randomized, double blind, placebo controlled, multicenter study evaluating the efficacy and safety of GDC-9545 combined with palbociclib compared…Giredestrant (RO7197597, GDC-9545) / Letrozole / Palbociclib | Roche | Ongoing |
| May 27, 2020 | An open-label, randomized, multicenter study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of pre- and postmenopausal women…Lasofoxifene | Sermonix Pharmaceuticals | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA